Autopsy report · NCT03874858
A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia
Cause of deathFunding or business
“Sponsor decision: The primary endpoint of the core/TF1 was achieved, and the sample size of Extension/TFR2 was unlikely to yield meaningful results. No new safety signals were observed. For these reasons, continuing the study was not justified.”
Life of this trial
- Ran for about 6 years 7 months before it stopped.
- 135 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- Nilotinib; Nilotinib; Asciminib
- Participants
- 135
- Sites
- 26
- Countries
- Italy
Trials that died the same way
- A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis
“Sponsor decision to early terminate the study based on the pre-defined futility criterion for efficacy. No safety concerns were identified.” - The Effects of High Energy Acoustic Shock Wave Therapy on Local Skin Perfusion and DFUs
“Mfr of product identified in protocol to measure perfusion after treatment with sponsor device withdrew support from the study. Sponsor decided to cancel the investigation due to lack of adequate replacement.” - Study of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure Patients
“Sponsor has designed another study with different endpoint to replace the current study”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.